For the quarter ending 2025-09-30, HUMAW made $753K in revenue. -$17,510K in net income. Net profit margin of -2325.37%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total revenue | 753 | 301 | ||
| Cost of goods sold | 260 | 213 | ||
| Research and development | 17,273 | 22,006 | ||
| Selling, general and administrative | 7,610 | 7,809 | ||
| Total operating expenses | 25,143 | 30,028 | ||
| Loss from operations | -24,390 | -29,727 | ||
| Interest income | 590 | 832 | ||
| Change in fair value of contingent earnout liability | -4,893 | 5,470 | ||
| Change in fair value of derivatives | 4,009 | -748 | ||
| Interest expense | 2,612 | 2,545 | ||
| Total other income (expense), net | 6,880 | -7,931 | ||
| Net loss | -17,510 | -37,658 | ||
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.11 | -0.24 | ||
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.11 | -0.24 | ||
| Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic (in shares) | 158,313,290 | 155,437,281 | ||
| Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in shares) | 158,313,290 | 155,437,281 | ||
Humacyte, Inc. (HUMAW)
Humacyte, Inc. (HUMAW)